| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Business Officer
2 companies
Pamela Esposito is Chief Business Officer at REPL and has filed Form 4s across 2 companies. Pamela Esposito's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.6M at current prices.
Historically, Pamela Esposito's trades have earned a strong insider score of 70/100 across 20 rated trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +28.4%.
The biggest single holding is REPL (~$5.4M) as Chief Business Officer. The REPL filings lean toward selling, a net 198,131 shares.
Pamela Esposito has 38 Form 4 filings on record from July 2018 to June 2026, across 2 companies: Director at Kymera Therapeutics (KYMR), 2020–2026; Chief Business Officer at Replimune Group (REPL), 2018–2023.
The 87 reported transactions were 37 open-market sales, 34 option exercises, 13 option or other derivative awards and 3 stock awards.
Counted by filing, the open-market trades come to no purchases and 20 sales worth about $10.4M.
The largest open-market sale was 55,000 shares of REPL at an average $43.99 on January 19, 2021, about $2.4M.
11 of the 12 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other was not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 2,500 | $79.15 | $197,877.15 | - | +16.1% | - | |
| Feb 20, 2026 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 2,500 | $87.31 | $218,270.01 | - | -7.8% | - | |
| Jan 20, 2026 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 5,500 | $67.91 | $373,521.12 | - | +27.6% | - | |
| Dec 17, 2025 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 27,563 | $82.16 | $2,264,480.27 | - | -1.0% | - | |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 5,000 | $49.04 | $245,185.50 | - | -6.6% | +71.2% | |
| Dec 2, 2024 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 2,500 | $49.00 | $122,500.00 | - | -36.8% | +34.6% | |
| Sep 17, 2024 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 13,500 | $48.28 | $651,765.65 | - | -9.0% | +1.7% | |
| Sep 12, 2023 | REPL Replimune Group, Inc. | Chief Business Officer | Sale+OE10b5-1 | 5,658 | $20.01 | $113,213.58 | -2.1% | -61.2% | -45.9% | |
| Aug 22, 2023 | REPL Replimune Group, Inc. | Chief Business Officer | Sale+OE10b5-1 | 18,600 | $20.01 | $372,186.00 | -6.6% | -49.2% | -48.8% | |
| Aug 11, 2023 | REPL Replimune Group, Inc. | Chief Business Officer | Sale+OE10b5-1 | 1,400 | $20.00 | $28,000.00 | -0.5% | -42.4% | -52.0% |